tiprankstipranks
Trending News
More News >
Cantargia AB (DE:7V3)
FRANKFURT:7V3

Cantargia AB (7V3) Price & Analysis

Compare
1 Followers

7V3 Stock Chart & Stats


Financials

7V3 FAQ

What was Cantargia AB’s price range in the past 12 months?
Cantargia AB lowest stock price was €0.08 and its highest was €0.42 in the past 12 months.
    What is Cantargia AB’s market cap?
    Cantargia AB’s market cap is €26.41M.
      When is Cantargia AB’s upcoming earnings report date?
      Cantargia AB’s upcoming earnings report date is Aug 21, 2025 which is in 71 days.
        How were Cantargia AB’s earnings last quarter?
        Cantargia AB released its earnings results on May 13, 2025. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.017.
          Is Cantargia AB overvalued?
          According to Wall Street analysts Cantargia AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Cantargia AB pay dividends?
            Cantargia AB does not currently pay dividends.
            What is Cantargia AB’s EPS estimate?
            Cantargia AB’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Cantargia AB have?
            Cantargia AB has 248,611,650 shares outstanding.
              What happened to Cantargia AB’s price movement after its last earnings report?
              Cantargia AB reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.333%.
                Which hedge fund is a major shareholder of Cantargia AB?
                Currently, no hedge funds are holding shares in DE:7V3

                Company Description

                Cantargia AB

                Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.
                Similar Stocks
                Company
                Price & Change
                Follow
                Oncopeptides AB
                Xbrane Biopharma AB
                Isofol Medical AB
                Guard Therapeutics International AB
                Immunicum AB
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis